bluebird bio Announces Second Quarter 2024 Results Call Date
bluebird bio (Nasdaq: BLUE) has announced its upcoming conference call to discuss second quarter 2024 results and business updates. The call is scheduled for August 14, at 8:00 a.m. ET. Investors and interested parties can participate by dialing +1 (800) 715-9871 (U.S. and Canada) and providing the Conference ID 2776050. A live webcast will be available on the company's investor relations website, with a replay accessible for 90 days following the event. This announcement indicates that bluebird bio is preparing to share its financial performance and operational progress for Q2 2024, which could potentially impact the company's stock price based on the reported results and future outlook.
bluebird bio (Nasdaq: BLUE) ha annunciato la sua prossima conference call per discutere i risultati del secondo trimestre 2024 e aggiornamenti aziendali. La chiamata è programmata per il 14 agosto, alle 8:00 a.m. ET. Gli investitori e le parti interessate possono partecipare componendo il numero +1 (800) 715-9871 (U.S. e Canada) e fornendo l'ID Conferenza 2776050. Sarà disponibile un webcast in diretta sul sito web per le relazioni con gli investitori della società, con una registrazione accessibile per 90 giorni dopo l'evento. Questo annuncio indica che bluebird bio si sta preparando a condividere le sue performance finanziarie e i progressi operativi per il secondo trimestre 2024, che potrebbero potenzialmente influenzare il prezzo delle azioni della società in base ai risultati riportati e alle prospettive future.
bluebird bio (Nasdaq: BLUE) ha anunciado su próxima llamada de conferencia para discutir los resultados del segundo trimestre de 2024 y actualizaciones comerciales. La llamada está programada para el 14 de agosto, a las 8:00 a.m. ET. Los inversores y las partes interesadas pueden participar marcando +1 (800) 715-9871 (EE. UU. y Canadá) y proporcionando el ID de Conferencia 2776050. Habrá un webcast en vivo disponible en el sitio web de relaciones con inversores de la empresa, con una repetición accesible durante 90 días después del evento. Este anuncio indica que bluebird bio se está preparando para compartir su desempeño financiero y progreso operativo para el segundo trimestre de 2024, lo que podría impactar potencialmente el precio de las acciones de la compañía según los resultados informados y las perspectivas futuras.
bluebird bio (Nasdaq: BLUE)는 2024년 2분기 실적 및 사업 업데이트에 대한 컨퍼런스 콜을 발표했습니다. 이 콜은 8월 14일 오전 8시(동부 표준시)로 예정되어 있습니다. 투자자 및 관심 있는 당사자는 +1 (800) 715-9871 (미국 및 캐나다)로 전화하여 컨퍼런스 ID 2776050을 제공하면 참여할 수 있습니다. 회사의 투자자 관계 웹사이트에서 실시간 웹캐스트를 이용할 수 있으며, 이벤트 종료 후 90일 동안 재생할 수 있는 콘텐츠가 제공됩니다. 이 발표는 bluebird bio가 2024년 2분기 동안의 재무 성과 및 운영 진전을 공유할 준비를 하고 있음을 나타내며, 보고된 결과 및 향후 전망에 따라 회사의 주가에 잠재적인 영향을 미칠 수 있습니다.
bluebird bio (Nasdaq: BLUE) a annoncé sa prochaine conférence téléphonique pour discuter des résultats du deuxième trimestre 2024 et des mises à jour commerciales. L'appel est prévu pour le 14 août à 8h00 ET. Les investisseurs et les parties intéressées peuvent participer en composant le +1 (800) 715-9871 (États-Unis et Canada) et en fournissant l'identifiant de la conférence 2776050. Un webinaire en direct sera disponible sur le site web des relations avec les investisseurs de l'entreprise, avec une rediffusion accessible pendant 90 jours après l'événement. Cette annonce indique que bluebird bio prépare le partage de ses performances financières et de ses progrès opérationnels pour le deuxième trimestre 2024, ce qui pourrait potentiellement influencer le prix de l'action de l'entreprise en fonction des résultats rapportés et des perspectives futures.
bluebird bio (Nasdaq: BLUE) hat seine bevorstehende Telefonkonferenz angekündigt, um über die Ergebnisse des zweiten Quartals 2024 und Unternehmensupdates zu diskutieren. Die Konferenz ist geplant für den 14. August um 8:00 Uhr ET. Investoren und interessierte Parteien können teilnehmen, indem sie +1 (800) 715-9871 (USA und Kanada) anrufen und die Konferenz-ID 2776050 angeben. Ein Live-Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung zugänglich ist. Diese Ankündigung zeigt, dass bluebird bio sich darauf vorbereitet, seine finanzielle Leistung und den operativen Fortschritt für das zweite Quartal 2024 zu teilen, was potenziell den Aktienkurs des Unternehmens basierend auf den berichteten Ergebnissen und der zukünftigen Perspektive beeinflussen könnte.
- None.
- None.
To participate in the conference call, please dial +1 (800) 715-9871 (
To access the live webcast, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812763842/en/
Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
Source: bluebird bio, Inc.
FAQ
When will bluebird bio (BLUE) report its Q2 2024 earnings?
How can investors participate in bluebird bio's (BLUE) Q2 2024 earnings call?
Where can I find the replay of bluebird bio's (BLUE) Q2 2024 earnings webcast?
